The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutationsResearch in context

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutationsResearch in context

Summary: Background: Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of adjuvant EGFR-TKIs with observation in such patients by incorporating an established 14-gene molecular assay for ri...

Full description

Bibliographic Details
Main Authors: Yu Jiang, Yuechun Lin, Wenhai Fu, Qihua He, Hengrui Liang, Ran Zhong, Ran Cheng, Bingliang Li, Yaokai Wen, Huiting Wang, Jianfu Li, Caichen Li, Shan Xiong, Songan Chen, Jianxing Xiang, Michael J. Mann, Jianxing He, Wenhua Liang
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:EClinicalMedicine
Subjects:
Adjuvant therapy
EGFR-TKI
Non–small-cell lung cancer
Stage I
Risk stratification
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003826

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003826

Similar Items